Harvard Enterprise Faculty to Present Full Tuition Scholarships for College students with Best Monetary Want

Will increase affordability for college students from various socioeconomic backgrounds

BOSTON, Aug. 16, 2022 /PRNewswire/ — In an effort to make the Grasp of Enterprise Administration (MBA) diploma extra inexpensive and accessible to a wider array of scholars, Harvard Enterprise Faculty (HBS) introduced immediately that it’s going to present scholarships to cowl the overall value of tuition and course charges for these with the best monetary want—roughly 10 p.c of its scholar physique. The Faculty will even provide scholarship help to extra college students from center earnings backgrounds, constructing on the roughly 50 p.c of scholars who already obtain

Read More Read More

Wave Life Sciences Studies Fourth Quarter and Full Yr 2021 Monetary Outcomes and Supplies Enterprise Replace

Wave Life Sciences USA, Inc.

Medical information from a number of novel, PN-modified stereopure oligonucleotides for ALS/FTD, DMD, and HD anticipated in 2022

GalNAc-AIMers restore therapeutically related ranges of AAT for lung safety and scale back liver-damaging aggregates in preclinical examine; IND enabling toxicology research anticipated to provoke in 3Q 2022

FY2021 year-end money whole of $150.6 million offering runway into 2Q 2023

Wave to host investor convention name and webcast at 8:30 a.m. ET at present

CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines firm dedicated to delivering life-changing

Read More Read More

Cellectis Offers Enterprise Replace and Reviews 4th Quarter and Full Yr 2021 Monetary Outcomes

Cellectis Inc.

  • On monitor for deliberate 2022 IND submission for UCART20x22, our first allogeneic twin CAR T-cell product candidate, in B-cell non-Hodgkin’s Lymphoma

  • Two manufacturing websites at the moment are totally operational; on-track to dose sufferers with investigational medicinal merchandise manufactured in-house in 2022

  • Money place1 of $191 million as of December 31, 2021

  • Convention name scheduled for 8AM ET/2PM CET on March 4, 2022

NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) — Cellectis (Euronext Progress: ALCLS – Nasdaq: CLLS), a clinical-stage biotechnology firm utilizing its pioneering gene-editing platform to develop doubtlessly life-saving cell and gene therapies, introduced its

Read More Read More

Epizyme Stories Fourth Quarter and Full 12 months 2021 Monetary Outcomes and Gives Enterprise Replace

TAZVERIK® (tazemetostat) Internet Product Income of $11.6 Million for 4Q 2021; $30.9 Million for FY 2021

$85 Million in Gross Proceeds Raised in January 2022 Public Providing, Mixed with Latest Expense Reductions Introduced Immediately, Extends Money Runway into 3Q 2023

Firm Engaged in International Begin-up Actions for SYMPHONY-1; Information Updates Anticipated Throughout Pipeline Applications in 2022

CAMBRIDGE, Mass., March 01, 2022–(BUSINESS WIRE)–Epizyme (Nasdaq: EPZM), a completely built-in, commercial-stage biopharmaceutical firm creating and delivering transformative therapies for most cancers towards novel epigenetic targets, right now reported fourth quarter and full yr 2021 monetary outcomes and supplied enterprise and portfolio updates.

Read More Read More

Vaxart Offers Enterprise Replace and Stories Fourth Quarter and Full Yr 2021 Monetary Outcomes

Vaxart, Inc.

Firm begins 2022 with a number of energetic packages with knowledge readouts anticipated this yr

Preliminary knowledge from COVID-19 Part II examine anticipated within the first half of 2022 and knowledge from a number of norovirus research additionally anticipated this yr

Ended 2021 with $182.7 million in money, money equivalents and marketable securities

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) — Vaxart, Inc. (NASDAQ: VXRT) issued its enterprise replace right this moment for the fourth quarter and full yr 2021, reporting ahead momentum for the Firm, together with its oral norovirus and COVID-19 vaccine candidates.


Read More Read More

Allogene Therapeutics Experiences Fourth Quarter and Full 12 months 2021 Monetary Outcomes and Offers Enterprise Replace

Allogene Therapeutics, Inc.

  • AlloCAR T™ Research Resumed and At the moment Enrolling Sufferers Following Removing of Medical Maintain in January 2022

  • Section 1 Information from the ALPHA Trials in Relapsed/Refractory (RR) Non-Hodgkin Lymphoma Offered at ASH 2021 Demonstrated Potential for an AlloCAR T Product to be a Secure and Sturdy Various to Autologous Cell Remedy in CAR T Naïve Sufferers

  • Section 1 Information Offered at ASH 2021 from the ALLO-715 UNIVERSAL Trial in R/R A number of Myeloma Demonstrated Potential for an Allogeneic Anti-BCMA CAR T to Obtain Responses Much like Accepted Autologous CAR T Remedy with Added Advantage of

Read More Read More